PKI - PerkinElmer to acquire BioLegend for ~$5.25 billion in cash and stock

Atstock Productions/iStock via Getty Images Privately-held BioLegend is a provider of antibodies and reagents in areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bioprocessing. BioLegend has over 700 employees based in the U.S., with estimated 2022 revenues of $380 million. The deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine. PerkinElmer (PKI) has fully committed bridge financing from Goldman Sachs Bank USA for the cash portion. The combination is expected to be accretive to PerkinElmer's existing revenue growth and margin profile and provide an estimated $0.30 of adjusted EPS accretion in the first full year following close and more than $0.50 in the second year following closing. The combined company will generate immediate revenue synergies and reach $100 million annually by the fifth year following the transaction close, and no significant cost synergies are planned. The transaction will be the

For further details see:

PerkinElmer to acquire BioLegend for ~$5.25 billion in cash and stock